The EPC Enrichment and Enumeration Kit is designed for the enumeration of circulating EPCs (cEPCs) from peripheral blood, cord blood, or leukapheresis products as well as EPCs from bone marrow. To ensure reliable enumeration results, the EPCs are enriched during the procedure to increase the sensitivity of the flow cytometric analysis.
The kit contains all reagents for:
- red blood cell lysis,
- EPC enrichment,
- blocking of Fc receptor–mediated non-specific labeling of non-target cells,
- enumeration of EPCs based on expression of CD34, CD133, and CD309,
Related products for EPC Analysis Cocktail Kit, anti-human
The EPC Enrichment and Enumeration Kit is designed for the enumeration of circulating EPCs (cEPCs) from peripheral blood, cord blood, or leukapheresis products as well as EPCs from bone marrow. To ensure reliable enumeration results, the EPCs are enriched during the procedure to increase the sensitivity of the flow cytometric analysis.
The kit contains all reagents for:
- red blood cell lysis,
- EPC enrichment,
- blocking of Fc receptor–mediated non-specific labeling of non-target cells,
- enumeration of EPCs based on expression of CD34, CD133, and CD309,
- exclusion of CD14+ cells,
- exclusion of dead cells,
- isotype controls.
EPC Analysis Cocktail, anti-human containing:
- CD34 Antibody, anti-human, FITC (clone: AC136, isotype: mouse IgG2a)
- CD133/2 Antibody, anti-human, PE (clone: 293C3, isotype: mouse IgG2b)
- CD14 Antibody, anti-human, PerCP (clone: Tük4, isotype: mouse IgG2a)
- CD309 (VEGFR-2) Antibody, anti-human, APC (clone: ES-20E6, isotype: mouse IgG1)
EPC Control Cocktail CD309, anti-human containing:
- CD34 Antibody, anti-human, FITC (clone: AC136, isotype: mouse IgG2a)
- CD133/2 Antibody, anti-human, PE (clone: 293C3, isotype: mouse IgG2b)
- Isotype Control Antibody, mouse IgG1, APC (clone: IS5-21F5)
- CD14 Antibody, anti-human, PerCP (clone: Tük4, isotype: mouse IgG2a)
EPC Control Cocktail CD133, anti-human containing:
- CD34 Antibody, anti-human, FITC (clone: AC136, isotype: mouse IgG2a)
- Isotype Control Antibody, mouse IgG2b, PE (clone: IS6-11E)
- CD14 Antibody, anti-human, PerCP (clone: Tük4, isotype: mouse IgG2a)
Additionally
- EPC Enrichment Cocktail, anti-human
- FcR Blocking Reagent, human
- Red Blood Cell Lysis Solution (25×)
- Propidium Iodide Solution
Instrument details
Flow cytometer equipped with a red (640 nm) and a blue (488 nm) laser.
Identification and enumeration of CD34+CD309 (VEGFR-2/ KDR)+ and CD133+ endothelial progenitor cells from human peripheral blood, leukapheresis, cord blood, and bone marrow.
MS or MACSQuant® Columns.
Identification of CD34+ cells and CD133 specificity. Leukocytes after discrimination of debris and platelets and exclusion of dead cells and monocytes are shown. Cells were stained with CD34-FITC and Mouse IgG2b-PE representing the isotype control for CD133 staining. Cells were analyzed by flow cytometry.
Identification of CD34+CD133+ cells in the pre-enriched EPC sample. Leukocytes after discrimination of cell debris and platelets and exclusion of dead cells and monocytes are shown. Cells were stained with CD34-FITC and CD133/2 (293C3)-PE and analyzed by flow cytometry. The population in R4 was used for further analysis of CD133 and CD309 expression shown in figures 3 and 4.
Enumeration of CD34+CD133+CD309 (VEGFR-2/KDR)+ EPCs in the pre-enriched EPC sample. Leukocytes after discrimination of debris and platelets, exclusion of dead cells and monocytes are shown. Additionally, data were gated on CD34+ cells. Cells were stained with CD309 (VEGFR-2/KDR)-APC and CD133/2 (293C3)-PE and analyzed by flow cytometry.
Isotype control of CD309 staining in the pre-enriched EPC sample. Leukocytes after discrimination of debris and platelets, exclusion of dead cells and monocytes are shown. Additionally, data were gated on CD34+ cells. Cells were stained with CD133/2 (293C3)-PE and Mouse IgG1-APC representing the isotype control for CD309 (VEGFR-2/KDR) staining. Cells were analyzed by flow cytometry.
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
To access a Safety Data Sheet for a hazardous product or component in English or Swedish language, follow the link below and enter the catalog number of the product.
Please note, that the Safety Data Sheet has a cover sheet only in English language.
Should you wish a Safety Data Sheet (SDS) in other languages than English or Swedish, please contact Technical Support.
- Valgimigli, M. et al. (2004) CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 110: 1209-1212
- Kondo, T. et al. (2004) Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler. Thromb. Vasc. Biol. 24: 1442-1447
- Peichev, M. et al. (2000) Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 95: 952-958
- Vasa, M. et al. (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89: e1-e7
- Steiner, S. et al. (2005) Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis 181: 305-310
- Rafii, S. and Lyden, D. (2003) Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9: 702-712
- Hill, J. et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348: 593-600
- Urbich, C. and Dimmeler, S. (2005) Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int. 67: 1672-1676
- Werner, N. and Nickenig, G. (2006) Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler. Thromb. Vasc. Biol. 26: 257-266
- Massa, M. et al. (2005) Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105: 199-206
You have previously chosen International as your location.
What do you want to do?